(Q37776073)

23 August 2017

1 reference

title

Restoring circadian rhythms: a new way to successfully manage depression (English)

1 reference

23 August 2017

Review: Restoring circadian rhythms: a new way to successfully manage depression (English)

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

11 June 2024

0 references

Philip Gorwood

1

0 references

language of work or name

English

0 references

publication date

1 August 2010

1 reference

full work available at URL

23 August 2017

http://jop.sagepub.com/cgi/content/abstract/24/2/15

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663804

http://journals.sagepub.com/doi/pdf/10.1177/1359786810372981

11 June 2024

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

Journal of Psychopharmacology

11 June 2024

published in

1 reference

23 August 2017

volume

24

1 reference

23 August 2017

issue

2 Suppl

1 reference

23 August 2017

page(s)

15-19

1 reference

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Nocturnal temperature in affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Circadian abnormalities, molecular clock genes and chronobiological treatments in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Melatonin for the Treatment of Sleep Disturbances in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Circadian misalignment in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Antidepressants and the risk of suicidal behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Controlled trial of bright light for nonseasonal major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Circadian polymorphisms associated with affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Continuity of antidepressant treatment for adults with depression in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Effect of agomelatine in the chronic mild stress model of depression in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Persistence and compliance to antidepressant treatment in patients with depression: a chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

The circadian rhythm of plasma thyrotropin in depression and recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

24-hour profile of plasma norepinephrine in affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372981

Combined Total Sleep Deprivation and Light Therapy in the Treatment of Drug-Resistant Bipolar Depression

21 January 2018

series ordinal

4

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

Journal of Psychiatry & Neuroscience

11 June 2024

7

29

126

2004

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

11 June 2024

Biological Psychiatry

9

19

1215

1984

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

Modulation of voltage-dependent Ca2+ conductance by changing Cl- concentration in rat lactotrophs.

11 June 2024

series ordinal

23

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

International Clinical Psychopharmacology

11 June 2024

38

22

S9

2007

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms

11 June 2024

series ordinal

39

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

11 June 2024

41

23

3

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

International Clinical Psychopharmacology

11 June 2024

46

22

S1

2007

1 reference

https://api.crossref.org/works/10.1177/1359786810372981

11 June 2024

Identifiers

1 reference

23 August 2017

1 reference